{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T09:17:28Z","timestamp":1774084648379,"version":"3.50.1"},"reference-count":78,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Microbiol."],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.2217\/fmb-2016-0213","type":"journal-article","created":{"date-parts":[[2017,3,24]],"date-time":"2017-03-24T15:25:58Z","timestamp":1490369158000},"page":"655-670","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Ceftazidime\u2013Avibactam: Novel Antimicrobial Combination for the Treatment of Complicated Urinary Tract Infections"],"prefix":"10.1080","volume":"12","author":[{"given":"Jakhongir F","family":"Alidjanov","sequence":"first","affiliation":[{"name":"Clinic & Policlinic for Urology, Pediatric Urology & Andrology, Justus-Liebig University, Giessen, Germany"},{"name":"Outpatient Department, JSC \u201cRepublican Specialized Center of Urology\u201d, Tashkent, Uzbekistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moritz","family":"Fritzenwanker","sequence":"additional","affiliation":[{"name":"Clinic & Policlinic for Urology, Pediatric Urology & Andrology, Justus-Liebig University, Giessen, Germany"},{"name":"Institute for Medical Microbiology, Justus-Liebig University, Giessen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Clinic & Policlinic for Urology, Pediatric Urology & Andrology, Justus-Liebig University, Giessen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian M","family":"Wagenlehner","sequence":"additional","affiliation":[{"name":"Clinic & Policlinic for Urology, Pediatric Urology & Andrology, Justus-Liebig University, Giessen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2017,3,24]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199310283291808"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h6544"},{"key":"e_1_3_2_5_1","first-page":"Doc01","article-title":"Recurrent urinary tract infections and complications after symptomatic versus antibiotic treatment: follow-up of a randomised controlled trial.","volume":"14","author":"Bleidorn J","year":"2016","unstructured":"Bleidorn J ,Hummers-PradierE,SchmiemannG,WieseB,GagyorI.Recurrent urinary tract infections and complications after symptomatic versus antibiotic treatment: follow-up of a randomised controlled trial.Ger. Med. Sci.14,Doc01 (2016).","journal-title":"Ger. Med. Sci."},{"key":"e_1_3_2_6_1","first-page":"5","article-title":"[Are there alternatives to antimicrobial therapy and prophylaxis of uncomplicated urinary tract infections?].","volume":"6","author":"Naber KG","year":"2014","unstructured":"Naber KG ,AlidjanovJF.[Are there alternatives to antimicrobial therapy and prophylaxis of uncomplicated urinary tract infections?].Urologiia6,5 \u20138,10\u20133 (2014).","journal-title":"Urologiia"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2010.190"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.09.009"},{"key":"e_1_3_2_9_1","unstructured":"Centre for Evidence-Based Medicine .PhillipsB BallC SackettD BadenochD StrausS HaynesB.Oxford Centre for Evidence-Based Medicine \u2013 Levels of Evidence (March 2009).www.cebm.net\/oxford-centre-evidence-based-medicine-levels-evidence-march-2009\/"},{"key":"e_1_3_2_10_1","unstructured":"Grabe M BartolettiR Bjerklund-JohansenTEet al. Guidelines on Urological Infections. European Association of Urology (2015).https:\/\/uroweb.org\/wp-content\/uploads\/19-Urological-infections_LR2.pdf"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2014.10.061"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2008.02.035"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.14.146"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.06852-11"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0463.2008.00922.x"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(08)70041-0"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.08.011"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/CE.S40698"},{"issue":"10","key":"e_1_3_2_19_1","first-page":"2173","article-title":"Prevalence and antibiogram of Extended Spectrum beta-Lactamase (ESBL) producing Gram negative bacilli and further molecular characterization of ESBL producingEscherichia coli andKlebsiella spp.","volume":"7","author":"Sharma M","year":"2013","unstructured":"Sharma M ,PathakS,SrivastavaP.Prevalence and antibiogram of Extended Spectrum beta-Lactamase (ESBL) producing Gram negative bacilli and further molecular characterization of ESBL producingEscherichia coli andKlebsiella spp.JCDR7 (10),2173 \u20132177 (2013).","journal-title":"JCDR"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.2165\/11533040-000000000-00000"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00568-10"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh424"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2016.1201065"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1086\/595011"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1205073109"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2011.03.021"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-013-1218-9"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1039\/9781847555403-00105"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-443-06839-3.00022-9"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2000.tb02034.x"},{"key":"e_1_3_2_31_1","first-page":"165","article-title":"Vital signs: carbapenem-resistantEnterobacteriaceae.","volume":"62","author":"Kallen M","year":"2013","unstructured":"Kallen M ,RicksP,EdwardsJet al. Vital signs: carbapenem-resistantEnterobacteriaceae. Morb. Mortal Wkly Rep. 62,165 \u2013170 (2013).","journal-title":"Morb. Mortal Wkly Rep."},{"key":"e_1_3_2_32_1","unstructured":"Cubist Pharmaceuticals Inc. Cubist presents detailed results from positive Phase 3 trials of ceftolozane\/tazobactam at 2014 European congress of clinical microbiology and infectious diseases (ECCMID) (2014).www.businesswire.com\/news\/home\/20140509005384\/en\/Cubist-Presents-Detailed-Results-Positive-Phase-3"},{"key":"e_1_3_2_33_1","unstructured":"Forest Pharmaceuticals Inc. Highlights of prescribing information: avycaz (ceftazidime-avibactam) for injection for intravenous use (2015).www.allergan.com\/assets\/pdf\/avycaz_pi"},{"key":"e_1_3_2_34_1","unstructured":"Allergan plc. FDA Approves Allergan\u2019s sNDA for AVYCAZ\u00ae (ceftazidime and avibactam) to include new Phase III data in patients with complicated urinary tract infections (cUTI) including Pyelonephritis (2017).www.prnewswire.com\/news-releases\/fda-approves-allergans-snda-for-avycaz-ceftazidime-and-avibactam-to-include-new-phase-iii-data-in-patients-with-complicated-urinary-tract-infections-cuti-including-pyelonephritis-300398414.html"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30194-3"},{"key":"e_1_3_2_36_1","unstructured":"WHO .WHO model list of essential medicines 2013 (2013).www.who.int\/medicines\/publications\/essentialmedicines\/18th_EML_Final_web_8Jul13.pdf"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199549040-00008"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2011.07.077"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2010.09.006"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2006.07.008"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp255"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh358"},{"key":"e_1_3_2_43_1","unstructured":"Aszodi J FromentinC LampilasM RowlandsDA.Heterocyclic compounds as inhibitors of beta-lactamases Google Patents (2009).www.google.com\/patents\/US7612087"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014556652"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00756-10"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn320"},{"key":"e_1_3_2_47_1","first-page":"258","volume-title":"Wilson and Gisvold\u2019s Textbook of Organic Medicinal and Pharmaceutical Chemistry.","author":"Beale JM","year":"2011","unstructured":"Beale JM,Jr .Antimicrobial Antibiotics.In:Wilson and Gisvold\u2019s Textbook of Organic Medicinal and Pharmaceutical Chemistry.WilsonCO,BealeJM,BlockJH(Ed. ).Lippincott Williams & Wilkins Baltimore,MD, USA,258 \u2013329 (2011)."},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/10.suppl_C.1"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0168-2"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0013-7"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200969070-00003"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(83)90006-8"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-015-0283-9"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/12.2.119"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2011.07.026"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.485979"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku025"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku551"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05024-14"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00851-12"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00163-15"},{"key":"e_1_3_2_62_1","volume-title":"47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics.","author":"Merdjan H","year":"2007","unstructured":"Merdjan H ,TarralA,GirardAet al. Safety, single dose pharmacokinetics, and pharmacodynamics of \u03b2-lactamase inhibitor NXL104 in healthy young male adults. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics. 17\u201320 September,IL, USA (2007)."},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv170"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073076"},{"key":"e_1_3_2_65_1","unstructured":"Center for Drug Evaluation and Research US Food and Drug Administration. Avycaz (ceftazidime-avibactam) FDA summary review. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM425458.pdf"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04218-14"},{"key":"e_1_3_2_67_1","volume-title":"54th Interscience Conference on Antimicrobial Agents and Chemotherapy.","author":"Lagac\u00e9-Wiens P","year":"2014","unstructured":"Lagac\u00e9-Wiens P ,AdamH,DenisuikAet al. In vitro Activity of Ceftazidime-Avibactam (CAZ-AVI) and comparators against Gram-negative pathogens isolated from patients in Canadian hospitals in 2009\u20132013: CANWARD surveillance study. Presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA 5\u20139 September (2014)."},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.09.012"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.748653"},{"key":"e_1_3_2_70_1","unstructured":"U.S. Food and Drug Administration. Ceftazidime-avibactam briefing package (NDA 206494).www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM425458.pdf"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw378"},{"key":"e_1_3_2_72_1","volume-title":"Highlights of Prescribing Information.","author":"Allergan plc.","year":"2017","unstructured":"Allergan plc. Avycaz (ceftazidime-avibactam) for injection, for intravenous use. Highlights of Prescribing Information. 6 February 2017."},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.793"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks523"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30004-4"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2015.04.006"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-015-0347-x"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.05.003"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-013-0640-7"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01009-09"}],"container-title":["Future Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fmb-2016-0213","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:41:16Z","timestamp":1719124876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fmb-2016-0213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,24]]},"references-count":78,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.2217\/fmb-2016-0213"],"URL":"https:\/\/doi.org\/10.2217\/fmb-2016-0213","relation":{},"ISSN":["1746-0913","1746-0921"],"issn-type":[{"value":"1746-0913","type":"print"},{"value":"1746-0921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-11-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-03-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}